ArticleFrontiers in oncology2024

Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.

Yanfang Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.